Heinemann Lutz, Benesch Carsten, DeVries J Hans
Profil Institut für Stoffwechselforschung, Neuss, Germany.
J Diabetes Sci Technol. 2011 Nov 1;5(6):1363-72. doi: 10.1177/193229681100500607.
The development of an artificial pancreas (AP) made huge strides from 2006 to 2008 and a large number of activities are going on in this area of research. Until now, most AP systems under development were tested only under highly controlled conditions. The aim of our project, funded by the European Union, is to develop an AP system to such a level that it can be studied under daily life conditions at the home of patients with diabetes (hence AP@home). Based on a subcutaneous-subcutaneous closed-loop strategy (i.e., glucose sensing and insulin infusion in the subcutaneous tissue), two different approaches will be taken to achieve this aim: a two-port AP system and a single-port AP system. The two-port AP system will use off-the-shelf-components for the glucose sensor and insulin pump in combination with closed-loop algorithms generated in Europe. As to the single-port AP system, two different innovative single-port systems will be developed; in this case, continuous glucose monitoring and insulin infusion will take place via a single catheter. The first clinical trials with the two-port AP system under controlled clinical conditions have started and good progress has been made in the development of the single-port AP systems. We believe that our consortium of 12 European partners, which builds on existing achievements and close cooperation between academic centers and industry, can contribute substantially to the development of an AP system that can be used by patients in daily life.
从2006年到2008年，人工胰腺（AP）的发展取得了巨大进展，该研究领域正在开展大量活动。到目前为止，大多数正在研发的AP系统仅在高度受控的条件下进行测试。我们这个由欧盟资助的项目的目标是，将AP系统开发到能够在糖尿病患者家中的日常生活条件下进行研究的水平（即居家人工胰腺）。基于皮下-皮下闭环策略（即在皮下组织中进行葡萄糖传感和胰岛素输注），将采用两种不同的方法来实现这一目标：双端口AP系统和单端口AP系统。双端口AP系统将把葡萄糖传感器和胰岛素泵的现成组件与欧洲生成的闭环算法结合使用。至于单端口AP系统，将开发两种不同的创新型单端口系统；在这种情况下，连续血糖监测和胰岛素输注将通过单个导管进行。在受控临床条件下对双端口AP系统进行的首次临床试验已经启动，单端口AP系统的开发也取得了良好进展。我们相信，我们这个由12个欧洲合作伙伴组成的联盟，以学术中心和产业界现有的成就及密切合作为基础，能够为开发出可供患者在日常生活中使用的AP系统做出重大贡献。
